Last updated: September 2, 2026
Belzutifan, marketed by Merck as Welireg, is a first-in-class oral hypoxia-inducible factor-2 alpha, or HIF-2α, inhibitor. Its commercial base began with von Hippel-Lindau disease and expanded into advanced renal cell carcinoma after prior immunotherapy and VEGF-targeted treatment. Merck reported Welireg sales of approximately $452 million in 2023, up from about $250 million in 2022, according to its annual report.[1]
The drug’s near-term growth depends on adoption in renal cell carcinoma, while its long-term value depends on earlier-line treatment trials, combination regimens, international approvals, and protection against generic entry. The principal commercial constraints are a restricted treatment sequence in RCC, competition from established immunotherapy and tyrosine kinase inhibitor combinations, and the absence of a large patent moat comparable with major biologic franchises.
What is belzutifan and how does Welireg work?
Belzutifan inhibits HIF-2α, a transcription factor activated by loss of von Hippel-Lindau protein function. HIF-2α signaling supports tumor-cell survival, angiogenesis, proliferation, and erythropoietin production.
Welireg is supplied as an oral tablet and is administered at 120 mg once daily for approved adult indications. The principal safety risks are anemia, hypoxia, and embryo-fetal toxicity. The mechanism also creates a commercially relevant anemia-management burden, particularly in heavily pretreated oncology patients.[2]
| Attribute |
Belzutifan |
| Brand |
Welireg |
| Active ingredient |
Belzutifan |
| Developer and marketer |
Merck & Co. |
| Mechanism |
Selective HIF-2α inhibition |
| Dosage form |
Oral tablet |
| Standard adult dose |
120 mg once daily |
| Initial U.S. approval |
August 13, 2021 |
| Initial indication |
VHL-associated RCC, CNS hemangioblastomas, and pancreatic neuroendocrine tumors |
| Expanded U.S. indication |
Advanced RCC after prior PD-1/PD-L1 inhibitor and VEGF-TKI therapy |
| FDA pathway |
Accelerated approval for the initial VHL indication; subsequent traditional approval for advanced RCC |
| Therapeutic category |
Targeted oncology |
What FDA approvals support the Welireg market?
The FDA approved Welireg in 2021 for adults with von Hippel-Lindau disease who require treatment for associated RCC, CNS hemangioblastomas, or pancreatic neuroendocrine tumors and do not require immediate surgery.[3]
The VHL approval was based on tumor response and durability in Study 004. VHL is a rare inherited cancer syndrome, so the initial addressable population was small. The approval nevertheless created a disease-specific market with limited direct pharmacologic competition.
In December 2023, the FDA approved Welireg for adults with advanced RCC following treatment with a PD-1 or PD-L1 inhibitor and a VEGF-TKI.[4] The approval was supported by LITESPARK-005, a randomized Phase 3 trial comparing belzutifan with everolimus. The trial improved progression-free survival in the prespecified analysis, although overall survival and response outcomes limited the degree of differentiation against established treatment options.[5]
The RCC label is commercially more important than the VHL label because it addresses a substantially larger population. The restriction to patients who have received both immunotherapy and VEGF-targeted therapy limits immediate volume but provides a regulatory foothold in the post-treatment setting.
How large is the belzutifan market opportunity?
The market is divided into three segments:
- VHL-associated tumors.
- Post-immunotherapy and post-VEGF-TKI advanced RCC.
- Potential future uses in earlier-line RCC and other HIF-2α-dependent cancers.
VHL market
The VHL market is small but strategically attractive. Patients may require repeated treatment for multifocal kidney tumors, pancreatic neuroendocrine tumors, and CNS hemangioblastomas. Belzutifan can delay or reduce the need for organ-directed surgery.
The commercial limitations are the low prevalence of VHL and the concentration of care in specialist centers. The indication is unlikely to generate blockbuster revenue by itself, but it supports premium pricing and establishes clinical familiarity with HIF-2α inhibition.
Advanced RCC market
The post-VEGF-TKI and post-checkpoint inhibitor RCC population is materially larger. U.S. kidney cancer incidence exceeds 80,000 new cases annually, although only a fraction develop metastatic disease and reach the labeled treatment sequence.[6]
Welireg competes in a crowded market that includes:
- Everolimus.
- Lenvatinib-based regimens.
- Cabozantinib.
- Tivozanib.
- Nivolumab-based treatment in earlier lines.
- Axitinib, pembrolizumab, and other immunotherapy-VEGF combinations before progression.
Belzutifan’s positioning is strongest where physicians want a non-VEGF oral mechanism after prior exposure to both immunotherapy and VEGF inhibition. Its differentiation is weaker when treatment choice is driven primarily by response rate, overall survival, treatment familiarity, or payer restrictions.
Earlier-line opportunity
The largest value inflection would come from a positive earlier-line RCC indication. Merck has studied belzutifan in combination with pembrolizumab and lenvatinib, as well as in other LITESPARK programs. Earlier-line use would expand the patient pool and increase treatment duration.
The commercial risk is that HIF-2α inhibition may not displace established immunotherapy-VEGF combinations unless trials show clear gains in overall survival, progression-free survival, tolerability, or quality of life. A combination that increases anemia or monitoring requirements without a clear efficacy advantage would face substantial market resistance.
What are Welireg’s reported sales and financial trajectory?
Merck reported strong growth after the initial VHL launch and before the full commercial contribution of the RCC approval.
| Fiscal year |
Welireg sales |
Approximate year-over-year change |
Main commercial driver |
| 2022 |
Approximately $250 million |
Not comparable to launch year |
VHL adoption and specialty-center expansion |
| 2023 |
Approximately $452 million |
Approximately 81% |
VHL growth and preparation for RCC launch |
| 2024 onward |
Dependent on RCC uptake |
Not stated here without a verified annual filing |
Broader RCC use and treatment duration |
The 2023 result indicates that the VHL business had already become commercially meaningful before the RCC label expansion. The next phase should be judged by four metrics:
- New patient starts in advanced RCC.
- Persistence and duration of therapy.
- Net price after rebates and payer discounts.
- Growth in combination-trial opportunities.
A reasonable commercial framework is:
| Scenario |
Market development |
Revenue implication |
| Downside |
RCC uptake remains limited to later-line patients; price pressure increases |
VHL-led franchise with modest growth |
| Base case |
Consistent post-immunotherapy and post-VEGF-TKI adoption; stable duration |
Meaningful oncology product with potential for high hundreds of millions in annual sales |
| Upside |
Positive earlier-line or combination data; broader international approvals |
Potential for multibillion-dollar annual sales |
| Severe downside |
Negative pivotal trials, safety limitations, or strong competitor differentiation |
Growth slows after initial RCC launch |
Welireg does not have the scale of Merck’s Keytruda franchise. Its value lies in creating a differentiated oncology platform around HIF-2α rather than replacing Merck’s established immunotherapy revenue.
When does belzutifan lose exclusivity?
Belzutifan’s commercial exclusivity is supported by regulatory exclusivity and patents. The first U.S. approval occurred in August 2021. The VHL indication received orphan-drug designation, which generally provides seven years of U.S. orphan exclusivity for the approved indication, subject to statutory exceptions. That period would generally run into 2028.[3]
The later RCC approval does not automatically restart the orphan period. It expands the label but does not create a new seven-year orphan period for the broader RCC population.
| Protection category |
Relevant timing |
Commercial effect |
| New chemical entity exclusivity |
Runs from first approval, subject to overlap rules |
Delays certain abbreviated applications |
| Orphan-drug exclusivity |
Generally seven years for the qualifying VHL indication |
Protects the VHL indication, not necessarily all uses |
| Patent protection |
Depends on issued patents, terminal disclaimers, pediatric extensions, and Orange Book listings |
Determines the practical generic-entry date |
| Pediatric exclusivity |
Applies only if granted after qualifying pediatric studies |
Could add six months to applicable protection |
| Data exclusivity for RCC |
Depends on the approval pathway and applicable FDA rules |
Does not necessarily block all patent-based challenges |
The exact generic-entry date must be determined from the current FDA Orange Book, issued patent records, patent-term-adjustment calculations, and any litigation settlements. Patent expiry is not necessarily the same as the earliest possible ANDA launch date.
What patents protect Welireg and belzutifan?
Belzutifan protection is expected to include several patent categories:
Compound patents
These cover the chemical structure of belzutifan and related HIF-2α inhibitors. Compound claims typically provide the strongest protection because they can block sale of the active ingredient regardless of dosage form or indication.
Pharmaceutical-composition patents
These may cover tablets, solid-state forms, excipients, particle characteristics, or manufacturing attributes. Formulation claims are relevant if the active compound patent expires before the formulation claims.
Method-of-use patents
Potential claims may cover treatment of VHL-associated tumors, RCC, combinations with checkpoint inhibitors, or biomarker-defined populations. Method-of-use patents are more vulnerable to design-around strategies and may not prevent all generic sales.
Manufacturing patents
Process patents can raise cost and complexity for a generic manufacturer but generally create a weaker barrier than valid compound claims. They matter most where the synthesis is difficult, yields are low, or a specific crystalline form is commercially necessary.
The Orange Book status should be reviewed for listed patents, patent-use codes, and regulatory-exclusivity dates. No broad biosimilar pathway applies because belzutifan is a chemically synthesized small molecule, not a biologic.
Are generic companies challenging Welireg with Paragraph IV filings?
A Paragraph IV challenge would assert that a listed patent is invalid, unenforceable, or not infringed. Such a filing can trigger patent litigation and a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory conditions.[7]
No material public Paragraph IV litigation is identified in the cited record through the 2023 reporting period. The absence of a reported challenge does not establish that no confidential or recently filed ANDA activity exists. For investors, the critical signals are:
- An FDA Paragraph IV notice received by Merck.
- District-court litigation within 45 days of notice.
- A tentative ANDA approval.
- A settlement providing a licensed generic-entry date.
- Patent-list corrections or additions in the Orange Book.
Generic launch risk is likely to remain low before the earliest surviving compound or composition patents, then rise sharply if multiple manufacturers can use the same active ingredient and no meaningful formulation barrier remains.
What is the competitive landscape for HIF-2α inhibitors?
Belzutifan has a first-mover advantage, but its mechanism is no longer without competition.
Merck versus potential HIF-2α competitors
Roche’s MK-6482-related rights and other pharmaceutical-company programs have increased interest in HIF-2α inhibition. The most commercially important competitor is Bristol Myers Squibb’s nivolumab plus cabozantinib franchise in RCC, not another HIF-2α inhibitor. In the near term, belzutifan must compete against established treatment pathways rather than only against mechanistically similar drugs.
| Competitive factor |
Welireg position |
| Mechanistic differentiation |
Strong |
| Clinical familiarity |
Increasing |
| VHL specialization |
Strong |
| Earlier-line RCC evidence |
Dependent on trial outcomes |
| Oral administration |
Advantage |
| Anemia risk |
Disadvantage |
| Established survival data versus RCC standards |
Less mature |
| Biosimilar exposure |
None |
| Generic exposure |
Future small-molecule risk |
What licensing deals and corporate transactions support belzutifan?
Merck acquired Peloton Therapeutics in 2019 for approximately $2.2 billion, including upfront and contingent consideration.[8] The transaction provided Merck with Peloton’s HIF-2α inhibitor program and positioned belzutifan as a strategic oncology asset.
The acquisition reduced external licensing complexity because Merck controls the principal commercial rights. It also transferred development risk to Merck before the drug had established revenue. The return on that investment depends on whether belzutifan expands beyond rare-disease use into major RCC segments.
What litigation and settlement risks affect Welireg?
The main future litigation risk is Hatch-Waxman litigation over compound, formulation, method-of-use, and process patents. A generic applicant may challenge only selected Orange Book patents while accepting others, which can produce staggered outcomes.
Potential settlement structures include:
- A delayed generic launch before the last patent expiry.
- An authorized generic arrangement.
- A license limited to certain indications.
- A covenant not to sue for specific patent claims.
- A settlement conditioned on regulatory approval or patent validity.
No major public belzutifan patent settlement is reflected in the cited sources through the 2023 reporting period. The later RCC indication may increase the value of method-of-use claims but does not necessarily extend compound protection.
What geographic markets can support belzutifan growth?
The United States is the primary commercial market because the initial approvals and early specialist adoption occurred there. International growth depends on regulatory filings, reimbursement, local treatment guidelines, and Merck’s ability to establish HIF-2α inhibition as a standard option in RCC.
The geographic opportunity is uneven:
- United States: strongest near-term revenue base and clearest regulatory positioning.
- Europe: opportunity depends on centralized authorization and reimbursement decisions.
- Japan: potential demand in RCC and rare VHL disease, subject to local approval.
- China: large RCC population but more intense pricing and local-competition pressure.
- Other markets: smaller near-term contribution and greater access variability.
Manufacturing is unlikely to create a biologics-style barrier. Belzutifan is an oral small molecule, so commercial supply depends on active pharmaceutical ingredient capacity, tablet production, quality controls, and regulatory compliance rather than cell-line or cold-chain infrastructure.
How strong is the belzutifan commercial and patent estate?
The commercial estate is strong in mechanism and clinical differentiation but narrower in market breadth than a broad immuno-oncology franchise.
| Dimension |
Assessment |
| Scientific differentiation |
Strong |
| Initial rare-disease position |
Strong |
| RCC market size |
Large |
| Current labeled RCC position |
Narrower later-line segment |
| Safety profile |
Manageable but anemia is commercially relevant |
| Patent durability |
Requires Orange Book and issued-patent review |
| Generic risk before core patent expiry |
Low |
| Generic risk after core patent expiry |
High |
| Biosimilar risk |
Not applicable |
| Revenue visibility |
Moderate |
| Upside from new indications |
High but trial-dependent |
Key Takeaways
- Belzutifan is Merck’s first commercial HIF-2α inhibitor and the company’s main asset in the VHL/HIF-2α disease pathway.
- Welireg sales increased from approximately $250 million in 2022 to approximately $452 million in 2023.[1]
- The 2023 RCC approval expanded the opportunity beyond rare VHL disease but placed the drug in a crowded later-line treatment market.
- Earlier-line RCC or combination approvals are the largest potential revenue catalysts.
- Anemia and treatment-sequence restrictions are the principal commercial limitations.
- Belzutifan is a small molecule, so biosimilar competition does not apply.
- The decisive generic-entry issues are compound-patent expiry, Orange Book listings, Paragraph IV activity, and any Merck settlement.
- Merck’s $2.2 billion Peloton acquisition made belzutifan a strategic oncology investment rather than a narrow rare-disease product.[8]
FAQs About Belzutifan Market Dynamics
What is the expected peak sales potential of Welireg?
Welireg could reach high hundreds of millions of dollars annually under a later-line RCC base case. Multibillion-dollar sales require successful earlier-line or combination use and broader international uptake.
Is belzutifan a competitor to Keytruda?
Belzutifan is not a direct substitute for Keytruda. It is a targeted oral therapy that may be used after or alongside immunotherapy in RCC development programs. Both products are owned by Merck, so the company may manage them as complementary assets.
Does belzutifan have orphan-drug exclusivity?
The VHL indication received orphan-drug protection associated with the 2021 approval. That protection generally runs for seven years, but it does not automatically extend to the later RCC indication.
What is the primary safety issue affecting belzutifan adoption?
Anemia is the principal treatment-limiting safety issue. Hypoxia is also clinically relevant, and the FDA label includes warnings and monitoring requirements for both risks.[2]
Can a generic manufacturer launch belzutifan before all patents expire?
Potentially, but only under specific legal conditions. A generic applicant may prevail in Paragraph IV litigation, obtain a license, launch after a settlement date, or enter after the last enforceable patent expires. FDA regulatory exclusivity and patent protection must be analyzed separately.
References
-
Merck & Co., Inc. (2024). 2023 annual report. https://www.merck.com/investor-relations/financial-information/annual-reports-and-proxy-statements/
-
U.S. Food and Drug Administration. (2023). Welireg (belzutifan) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (2021, August 13). FDA approves belzutifan for von Hippel-Lindau disease. https://www.fda.gov/drugs/resources-information-approved-drugs/
-
U.S. Food and Drug Administration. (2023, December 14). FDA approves belzutifan for advanced renal cell carcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/
-
Merck & Co., Inc. (2023). Merck announces phase 3 LITESPARK-005 results for Welireg in advanced renal cell carcinoma. https://www.merck.com/news/
-
National Cancer Institute. (2024). Renal cell cancer statistics. https://www.cancer.gov/types/kidney
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and 30-month stays under Hatch-Waxman. https://www.fda.gov/drugs/
-
Merck & Co., Inc. (2019, April 17). Merck to acquire Peloton Therapeutics. https://www.merck.com/news/
